Novo Nordisk's Biggest Strength and Weakness
Is Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?
HP up 6% on strong quarter
HP stock soars on strong fourth-quarter
Is Novo Nordisk Still an Attractive Investment?
Despite a bumpy 2013, largely caused by the FDA rejection of its drug Tresiba, is Novo Nordisk a stock to add to your watchlist?